Caroline Ingre's research group
ALS (amyotrophic lateral sclerosis) is a fatal neuromuscular disease that is characterized by a degeneration of upper and lower motorneurons. The patients experience a weakness usually starting in the upper or lower extremities spreading to other regions weakening both speech and swallowing. Besides the muscle weakness, cognitive dysfunction and behavioral changes are seen in about 50% of the patients and some develop fulminant frontotemporal dementia.
There is no single test that provides the ALS diagnosis. The diagnosis is based on clinical and electrophysiological signs, and the exclusion of other diseases. Little information can thus be given to the patient about the course of the disease. The disease has no cure. The aim with our research is to increase the knowledge about several aspects of the disease, and ultimately find a cure.
My group works within many areas of the ALS disease. We have created a national quality registry, a tissue biobank, an imaging bank and collected data on lifestyle and environment. We also conduct clinical trials on ALS.
- Risc and correlations to exposure
- Spreading patterns and phenotypic expression
- Prognosis and survival
- Quality of life and depression
- Cognitive status
- Tissue biomarkers
- Imaging biomarkers
- Genetic expression
- Clinical trials
Lipids, Apolipoproteins, and Prognosis of Amyotrophic Lateral Sclerosis.
Caroline Ingre;Lin Chen; Yiqiang Zhan; Jet Termorshuizen; Li Yin; Fang Fang
Neurology. 2020, April.
Peripheral immune biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow-up.
Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, et al
Ann. Neurol. 2019 Dec;86(6):913-926
The Swedish motor neuron disease quality registry.
Longinetti E, Regodón Wallin A, Samuelsson K, Press R, Zachau A, Ronnevi LO, et al
Amyotroph Lateral Scler Frontotemporal Degener 2018 11;19(7-8):528-537
Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
Mariosa D, Hammar N, Malmström H, Ingre C, Jungner I, Ye W, et al
Ann. Neurol. 2017 May;81(5):718-728
Risk factors for amyotrophic lateral sclerosis.
Ingre C, Roos PM, Piehl F, Kamel F, Fang F
Clin Epidemiol 2015 ;7():181-93